Select a featured project from the list below to view more details:

ANTI-CANCER COMPOUNDS THAT TARGET THE MEMBRANE STEROID STEROID RECEPTORS
NOVEL SPIROSTEROID MOLECULES WITH POTENT NEURO-PROTECTIVE, AND NEURO-REGENERATIVE ACTIVITIES

ANTI-CANCER COMPOUNDS THAT TARGET THE MEMBRANE STEROID STEROID RECEPTORS
Bionature has developed proprietary anti-cancer molecules, based on natural compounds and has demonstrated their effectiveness in the selective identification and elimination of tumor cells derived from solid cancers.

This project involves the use of such molecules and other steroid-protein conjugates that exhibit potent cytotoxic actions in prostate cancer cells, as a new primary of adjuvant chemotherapy for solid cancers and hematological malignancies. Bionature has patents and patent applications that cover the use of these compounds in treating, preventing or ameliorating diseases involving the action of a membrane androgen receptor (mAR).

Androgens were one family of the steroids reported to exert membrane-initiated effects. While no definite indication of the molecular nature of mARs has been determined, signalling via mARs has been shown to involve ion movements, secretion of intracellular proteins, the initiation of rapid signalling cascades leading to actin cytoskeleton modifications and transcription of specific genes independent from those triggered by the action of androgen nuclear receptors. mARs have been reported in a number of normal or malignant tissues and lesions and they have attracted interest as therapeutic targets for disorders influenced by the action of membrane androgen receptors, particularly cancer. The mAR is structurally and functionally distinct from the intracellular androgen receptor.

Bionature has developed a collection of membrane androgen receptor ligands (MARLs) that can kill cancer cells and are are good candidates for clinical development for prostate cancer treatment. Bionature EA, Ltd. is currently seeking worldwide strategic partners to continue development its mAR ligand technology for the treatment of cancer patients currently also receiving other drugs like paclitaxel. The opportunity also exists for the licensing of specific membrane steroid receptor agonists that are being developed as anti-tumor agents. Bionature has several patents and applications including 2 published US patents (US 7,358,379 and 7,495,115). The MARLs under development have also been shown to act as enhancers of erythropoietin action in haemopoietic and non-haemopoietic tissues (patent applications pending).


NOVEL SPIROSTEROID MOLECULES WITH POTENT NEURO-PROTECTIVE, AND NEURO-REGENERATIVE ACTIVITIES
Neuronal cell death by apoptosis is the ‘end-point’ of many human neurological disorders, including Alzheimer's, Parkinson's and Huntington's diseases, stroke/trauma, multiple and amyotrophic lateral sclerosis. Additionally, brain ischemia and trauma induce necrosis of a small brain area, which then propagates neuronal cell loss by apoptosis to a larger brain area, due to the neurotoxic material released by the necrotic cells. Apoptotic neuronal cell loss is also observed in the ageing brain, as a physiological process. Currently, there is little or no treatment for most neurodegenerative diseases. A fundamental approach for reducing the burden of neurodegenerative diseases is to slow or halt progression, and ultimately, to prevent the onset of the disease process. Thus, strategies for neuroprotection, preventing apoptotic neuronal cell loss may offer new therapeutic interventions.

Bionature had developed novel spirosteroid molecules that possess anti-apoptotic, neuro-protective activity and are apparently devoid of any hormonal side effects. These molecules interact with NGF receptors, activating major pro-survival, anti-apoptotic signalling in degenerative neurons, addressing the pressing need for the discovery of new compounds for neural cell protection, repair and rescue. Bionature’s research in a number of widely accepted mouse models of neurological disease and in stem cells has demonstrated that its proprietary molecules are effective in preventing neuronal apoptosis and in inducing neurogenesis.

Bionature is currently seeking worldwide strategic partners to continue developing its neuroprotective compounds for the safe and effective treatment of neurodegenerative diseases, such as Multiple Sclerosis (three of Bionature’s compounds efficiently reverse paralysis of EAE mice, modulating Th17 response and neuronal apoptosis). The invention provides pharmaceutical compositions and methods of treating various neurodegenerative diseases. Bionature has several international patent applications pending and is actively investigating the efficacy of its proprietary compounds in in vitro and in vivo experimental models